Untargeted proteomics enables ultra-rapid variant prioritization in mitochondrial

and other rare diseases

- 4 Daniella H. Hock^{1,2,3,*}, Nikeisha J. Caruana^{1,4}, Liana N. Semcesen¹, Nicole J. Lake⁵, Luke
- 5 E. Formosa⁶, Sumudu S. C. Amarasekera², Tegan Stait², Simone Tregoning², Leah E.
- 6 Frajman², David R. L. Robinson¹, Megan Ball^{2,10,12}, Boris Reljic^{1,6}, Bryony Ryder⁷, Mathew
- 7 J. Wallis^{8,9}, Anand Vasudevan¹⁰, Cara Beck³, Heidi Peters^{11,12}, Joy Lee^{3,11}, Natalie B.
- 8 Tan^{2,3,12}, Mary-Louise Freckmann¹³, MitoMDT Diagnostic Network for Genomics and
- 9 Omics**, Vasiliki Karlaftis^{2,12}, Chantal Attard^{2,12}, Paul Monagle^{2,12,14,15}, Amanda
- 10 Samarasinghe², Rosie Brown^{2,3}, Weimin Bi^{16,17}, Monkol Lek⁵, Robert McFarland^{18,19},
- 11 Robert W. Taylor^{18,19}, Michael T. Ryan⁶, Zornitza Stark^{2,3,12}, John Christodoulou^{2,3,12},
- 12 Alison G. Compton^{2,3,12}, David R. Thorburn^{2,3,12*}, David A. Stroud^{1,2,3*}
- 14 Affiliations

13

1

2

- 15 ¹Department of Biochemistry and Pharmacology, Bio21 Molecular Science and
- 16 Biotechnology Institute, The University of Melbourne, Melbourne, VIC, 3010, Australia
- 17 ²Murdoch Children's Research Institute, Melbourne, VIC 3052, Australia
- ³Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne,
- 19 VIC, 3052, Australia
- ⁴Institute for Health and Sport (iHeS), Victoria University, Melbourne, VIC, 3011, Australia
- 21 ⁵Department of Genetics, Yale School of Medicine, New Haven, CT 06510 USA
- ⁶Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery
- 23 Institute, Monash University, 3800, Melbourne, Australia
- ⁷Paediatric and Adult National Metabolic Service, Te Toka Tumai, Te Whatu Ora Health
- 25 New Zealand, Auckland, New Zealand
- ⁸Tasmanian Clinical Genetics Service, Tasmanian Health Service, Hobart, TAS 7001,
- 27 Australia
- ⁹School of Medicine and Menzies institute for Medical Research, University of Tasmania,
- 29 Hobart, TAS 7001, Australia
- 30 ¹⁰Royal Women's Hospital, Melbourne, VIC, 3052, Australia
- 31 ¹¹Department of Metabolic Medicine, Royal Children's Hospital, Melbourne, VIC 3052,
- 32 Australia
- 33 ¹²Department of Paediatrics, University of Melbourne, Melbourne, VIC 3010, Australia
- 34 ¹³Department of Clinical Genetics, The Canberra Hospital, Canberra, Australian Capital
- 35 Territory, Australia

- 36 ¹⁴Department of Haematology, Royal Children's Hospital, Parkville VIC, Australia
- 37 ¹⁵Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia
- 38 ¹⁶Department of Molecular and Human Genetics, Baylor College of Medicine, Houston,
- 39 TX, 77030, USA.
- 40 ¹⁷Baylor Genetics, Houston, TX, 77021, USA.
- 41 ¹⁸Mitochondrial Research Group, Translational and Clinical Research Institute, Faculty of
- 42 Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, United
- 43 Kingdom

51

54 55

56

57

58

59

60

61

62

63

64

65

66

67

68

- 44 ¹⁹NHS Highly Specialised Service for Rare Mitochondrial Disorders, Newcastle upon
- Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, NE1 4LP, UK
- 47 *To whom correspondence should be addressed. Tel: +61-3-8344-8317 Email:
- 48 <u>daniella.hock@unimelb.edu.au</u> (Daniella H. Hock) Tel: +61-3-8341-6235 Email:
- 49 <u>david.thorburn@mcri.edu.au</u> (David R. Thorburn); Tel: +61-3-8344-7316; Email:
- 50 <u>david.stroud@unimelb.edu.au</u> (David A. Stroud).
- **MitoMDT Diagnostic Network for Genomics and Omics members are listed at the end of the manuscript.

Abstract

Only half of individuals with suspected rare diseases receive a definitive genetic diagnosis following genomic testing. A genetic diagnosis allows access to appropriate patient care and reduces the number of potentially unnecessary interventions and related healthcare costs. Here, we demonstrate that an untargeted quantitative mass-spectrometry approach quantifying >6,000 proteins in primary fibroblasts representing >80% of known mitochondrial disease genes can provide functional evidence for 83% of individuals in a cohort of known primary mitochondrial diseases. We profiled >90 individuals, including 28 with confirmed disease and diagnosed 6 individuals with variants in both nuclear and mitochondrial genes. Lastly, we developed an ultra-rapid proteomics pipeline using minimally invasive peripheral blood mononuclear cells to support upgrade of variant pathogenicity in as little as 54 hours in critically ill infants with suspected mitochondrial disorders. This study supports the integration of a single untargeted proteomics test into routine diagnostic practice for the diagnosis of rare genetic disorders in clinically

actionable timelines, offering a paradigm shift for the functional validation of genetic variants.

Introduction

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

Despite advances in genomic sequencing approaches, only 35-70% of individuals with suspected rare disease receive a molecular diagnosis following whole exome sequencing (WES) or whole genome sequencing (WGS)¹⁻⁵. Negative cases generally remain undiagnosed due to variants being refractory to short-read sequencing approaches or when detected variants of uncertain significance (VUS, Class 3) are detected, requiring functional evidence to be upgraded to likely pathogenic (Class 4) or pathogenic (Class 5). Mitochondrial disease is an umbrella term for a group of over 300 rare monogenic disorders affecting mitochondrial energy production in the form of ATP⁶. These disorders can arise from sporadic or inherited variants in either nuclear or mitochondrial DNA (mtDNA), presenting at any stage of life with a myriad of symptoms affecting either a single organ or in a multisystemic manner⁷. Mitochondrial diseases affect approximately 1 in 5,000 live births⁸ with limited treatments available, reinforcing the importance of a genomic diagnosis for early intervention in affected individuals. A genomic diagnosis also facilitates informed reproductive options such as prenatal diagnosis (PND) and assisted reproductive technologies such as preimplantation genetic testing (PGT) and mitochondrial replacement therapy (MRT)⁹. Functional approaches to assess VUS pathogenicity in mitochondrial disease have historically relied on targeted and low throughput tests such as respiratory chain enzymology (RCE), SDS-polyacrylamide gel electrophoresis (PAGE) or Blue Native (BN)-PAGE and immunoblotting. RCE assesses the activity of the mitochondrial respiratory chain complexes I-IV and is typically normalised to the activity of a single enzyme, citrate synthase (CS), to account for variability in mitochondrial content determined by sample quality, amount and storage¹⁰. Western blotting has also been used for the confirmation of VUS pathogenicity based on protein abundance or differential size, although it relies on having a strong genetic lead for disease causation from genomic data and the commercial availability of antibodies for the desired protein.

Other non-targeted functional approaches such as transcriptomics and proteomics have also been applied to the diagnosis of mitochondrial diseases. In selected cohorts, transcriptomics has been shown to increase the diagnosis of mitochondrial disorders by 10-16%^{11, 12} and other rare Mendelian disorders by 7-17%¹³⁻¹⁵. Although transcriptomic analysis can be a powerful tool in assessing pathogenicity of intronic and splice variants, this approach has limited power in offering functional information on missense variants, one of the most common and challenging classes of variants to assess^{16, 17}. Splice variants are predicted to account for only 10% of pathogenic variants associated with autosomal recessive disorders¹⁸, in line with current diagnostic rates achieved by transcriptomics. Missense variants, on the other hand, account for 60% of pathogenic variants¹⁸ and approximately 40% of them are expected to result in reduced protein levels due to protein instability and turnover¹⁹. Proteomics can detect such changes and has been demonstrated to contribute to the diagnosis of Mendelian disorders by providing functional evidence for not only missense variants but also splice, deep intronic and copy number variants ^{11, 20-25}. Despite this, there is a lack of data to inform the general utility of proteomics in rare disease diagnoses as an untargeted approach like genomics and transcriptomics. Here, we present a systematic analysis demonstrating the utility of proteomics in the detection of rare mitochondrial disorders and provide the first validated pipeline for ultrarapid functional testing using peripheral blood mononuclear cells (PBMCs). Reference proteomics data and associated bioinformatics tools for performing the proteome analysis approaches developed for these investigations can be applied to user-uploaded data through our interactive web tool (https://rdmassspec.shinyapps.io/RDMSExplorer/).

Results

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

To validate our untargeted proteomic approach in the detection of mitochondrial disorders, we first analysed primary fibroblast cell lines from a cohort of 24 patients with confirmed genetic diagnoses based on known pathogenic or likely pathogenic nuclear or mtDNA-encoded variants. This validation cohort (VC) included cell lines with defects in subunits or assembly factors for each of the five individual OXPHOS complexes as well as defects of mtDNA translation that impact multiple complexes, causing a combined OXPHOS

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

biochemical defect (**Fig 1A**, **Supplementary Table 1**). Principal component analysis showed that proteomes segregate according to their primary defect (**Fig. 1B**) and hierarchical clustering of OXPHOS subunits and assembly factors identified clear profiles (**Supplementary Fig. 1A**, **B**). We have previously shown similar profiles to be present in gene-edited HEK293T knockout of Complex I subunits²⁶. Comparison of mitochondrial proteomes from our validation cohort of fibroblast cell lines and corresponding gene-edited HEK293T knockout cell lines (knockout cohort, KC) showed good correlation of dysregulated proteins (**Supplementary Fig. 2A, B**).

The maximum theoretical coverage of known mitochondrial disease gene products from the fractionated library was 80%, with a routine coverage of 64% in a standard 95-minute library-supported DIA run from fibroblast samples (Fig. 1C). Our approach could also detect proteins corresponding to 37% of the Mendeliome (i.e., encoded by known disease genes) in a standard 95-minute run, supporting the potential utility of proteomics as a disease agnostic test in the resolution of many rare monogenic disorders. In terms of variant type in the validation cohort, the most common type was nuclear single nucleotide variants (48%) followed by mtDNA single nucleotide variants (16%), indel (16%), splice site (13%) and deep intronic (6%) (Fig. 1D). We quantified the abundance of the protein of interest in 67% of our investigations with the most common outcome being the protein abundance readily quantified in controls and absent in proband (42%) followed by a decrease in the patient relative to controls (21%) (Fig. 1E). In 29% of cases the protein of interest was not detected in either proband or control fibroblasts. For the cases where the protein was identified in both proband and control fibroblasts, analysis of the standard deviation show that ND1 abundance in VC6 (MT-ND1) was 97% relative to control median and within the control distribution, while ND5 abundance in VC12 (MT-ND5) was 118% relative to control median and approximately 3 standard deviations above the control median (Fig. 1F). Other identified proteins were outside the control range and >9 standard deviations below control median (Fig. 1F).




Figure 1. Study design and validation cohort analysis A – Quantitative proteomics experimental design overview. A fibroblast validation cohort (VC), HEK293T knockout cohort (KC), undiagnosed patient cohort (UDP) and supporting cohort (SC) prepared using S-Trap[™] columns. Digested peptides were subjected to Liquid Chromatography tandem Mass Spectrometry (LC-MS/MS) Data Independent Acquisition (DIA). Pooled control peptides were fractionated using strong cation-exchange (SCX) chromatography and data acquired as Data Dependent Acquisition (DDA) to generate spectral libraries for fibroblasts (Fbs), HEK293T (HEK) and PBMCs. Raw data were searched using Spectronaut® software and data analyses were performed with a combination of Perseus software, Python and R. B - Principal Component Analysis (PCA) of the fibroblast validation cohort (N=24) relative to controls based on the differential abundance of whole cell proteins calculated from t-test. C - Venn diagram showing the coverage of Mendeliome (v. 0.12869, top panel) and Mitochondrial disease (v. 0.787, bottom panel) lists including green (diagnostic-grade) and amber (borderline diagnostic-grade) genes retrieved from PanelApp Australia²⁷. D - Summary of the genetic variant types analysed in the validation cohort (VC). E - Summary of the findings in the VC based on protein identification and abundance. In 42% (10/24) of the cases the protein expected to be affected by the genetic variant is not detected in the patient while it is detected in the controls. In 29% (7/24) of the cases, the protein is not detected via quantitative proteomics, in 21% (5/24) of the cases, the protein is decreased in abundance in the patient compared to the 5 controls, and in 4% (1/24) of the cases, the protein

162

163164

165

166

167

168

169

170

171

172

173

174

175

176

is increased compared to the controls analysed. SNV = single nucleotide variant. F - Protein standard deviation from control median of the respective affected gene in controls (purple) and probands (red) in the validation cohort (VC). Standard deviation was calculated from the median control variance.

178

179

180

181 182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

Mitochondrial content has previously been calculated in proteomics data using the mean abundance of experimentally validated mitochondrial proteins in the MitoCarta 3.0 database^{28, 29}. We noticed that the mean abundance of mitochondrial proteins as a group varied between cell lines in our validation cohort (Supplementary Fig. 3A) but not control individuals (Supplementary Fig. 3B). This phenomenon is typically taken into consideration in enzymology analyses by expressing enzyme rates as citrate synthase (CS) ratios to account for mitochondrial proliferation or cell/tissue variability^{10, 30}. CS enzyme activity in our validation cohort varied greatly (Supplementary Fig. 3A, upper panel), consistent with altered mitochondrial content. Surprisingly, while CS activity did have a weak positive correlation with the relative abundance of CS protein as detected by proteomics (Supplementary Fig. 3C, left panel), it did not correlate with mitochondrial content calculated from the abundance of mitochondrial proteins (Supplementary Fig. **3C**, middle panel). In line with this, CS protein abundance also did not correlate with mitochondrial content calculated from proteomics data (Supplementary Fig. 3C, right panel). Since the nature of proteomics-based RCA is relative protein abundance, we concluded that mean mitochondrial protein abundance is the appropriate metric to normalise proteomics data. We built a differential mitochondrial abundance correction step into our RCA calculations (see Materials and Methods for detailed information). This correction is of benefit for cell lines that may have different mitochondrial content to controls and corrects for mitochondrial content before calculating the relative abundance of each complex.

We next sought to systematically benchmark our RCA analysis against clinical RCE. RCE was performed on 23 of the 24 fibroblast lines in the validation cohort, and was also performed on skeletal muscle (SKM) or lymphoblastoid cell lines (LCLs) for 17 of the 24 patients. Results are presented relative to CS (**Supplementary Table 2**) and the Bernier criteria³¹ were used to classify results. Fibroblast RCE detected a definite defect (<30%, major criterion) in the expected complex(es) for 19 of 24 fibroblast lines (79%) while three

[VC4 (NDUFS2), VC7 (NDUFAF1) and VC10 (NDUFB10)] had a probable defect (minor criterion) and RCE did not detect a defect in VC19 (COX6B1) fibroblasts (Fig. 2A left panel, Supplementary Table 2). When skeletal muscle or LCLs were also available, RCE revealed a major defect in 9 of 17 of the analyses (53%), and a minor defect in four (23%) while three were not deficient (18%) and one was not available (6%)(Fig. 2A, right panel).

Relative complex abundance (RCA) analysis was performed incorporating the correction for mitochondrial content (**Supplementary Fig. 4**) as described above. We classified a major defect as an RCA abundance \leq 65% relative to controls or \leq 75% with absent detection of the protein of interest in the proband with >2 peptides detected in controls while minor defects were classified by an RCA abundance of \leq 75% relative to controls (**Supplementary Table 2**). Using these criteria, a major RCA defect was detected in 83% of the cell lines in the validation cohort, a minor defect in a single case, VC19 (COX6B1), and no defect was detected in three cell lines with mtDNA variants (**Fig. 2B**). Overall, there is no strong correlation between RCE activity and an RCA value relative to control (R=0.072, p=0.78) (**Fig. 2C**).

For isolated Complex I disorders, 83% (10/12 patients) had a complex I abundance lower than 75% relative to controls analysed (*p*<0.0001). Two of the three Complex I-deficient fibroblast lines harbouring missense mtDNA-encoded variants were refractory to RCA analysis but diagnostic by RCE. mtDNA variant heteroplasmy in fibroblasts was 92% for VC6 *MT-ND1* and 71% for VC12 *MT-ND5*, highlighting a limitation of our approach in the detection of some mtDNA-driven disorders. Importantly, in all 10 fibroblast lines where RCA was diagnostic for a Complex I disorder, lower abundance (<65% relative to controls) of Complexes III, IV and V were not noted (**Supplementary Fig. 4**). While Complex II was reduced to <75% in four of these, RCE similarly identified a probable Complex II defect for one (*FOXRED1*), supporting the accuracy and specificity of RCA analysis. In 7/7 individuals with isolated Complex II, III or IV disorders, the abundance of the relevant complex was reduced to <75% controls (**Fig. 2D**) however t-test significance varied, especially in CII and IV defects where the number of detected subunits was as

low as two. All were specific for the relevant isolated defect except for UQCRC2 where a Complex I abundance of 67% control (p<0.0001) was noted, as expected for Complex III disorders³².

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

For isolated disorders involving Complexes I-IV due to nuclear defects, we determine an RCA value in fibroblasts of <65% controls to be diagnostic. The same threshold may also be applied to isolated disorders caused by pathogenic variants in mtDNA including those leading to Complex V deficiency, however smaller reductions may not exclude pathogenicity as seen in VC6 (MT-ND1), VC12 (MT-ND5) and VC20 (MT-ATP6) (Fig. 2D). Interestingly, in the case of VC6 this was likely not due to heteroplasmy, which was 92% NC 012920.1(MT-ND1):m.3949C>T in fibroblasts. On the other hand, in VC12 the NC 012920.1(MT-ND5):m.13513G>A variant found at 71% in fibroblasts, did not show the expected RCA defect while it satisfied the major criteria in RCE (Supplementary **Table 2**), suggesting impaired enzyme kinetics in the absence of a structural Complex I defect. Finally, we found that defects directly impacting mitochondrial translation such as MRPS34 fibroblasts presenting with a destabilised mitochondrial ribosome small subunit²⁵, MT-TK which encodes the mitochondrial lysine transfer RNA³³, MTFMT which encodes the mitochondrial methionyl-tRNA formyltransferase³⁴, and FARS2 encoding mitochondrial phenylalanyl-tRNA synthetase, led to combined Complex I and IV defects that each met criteria of an RCA value <65% control (Fig. 2D), consistent with the major criterion observed in RCE (Supplementary Table 2). Taken together, fibroblast RCA detected an OXPHOS defect at <65% relative to controls in the expected complex(es) for 20 of 24 fibroblast lines tested (83%) (Fig. 2B). One fibroblast line, VC19 (COX6B1), had an RCA of 71% for Complex IV relative to controls, which is in line with a previous report showing remaining assembled complex³⁵ and the peripheral position of the late assembled COX6B1 subunit in the structure of Complex IV^{36, 37}. Three fibroblast lines where a definitive defect was not observed by RCA harboured variants in mtDNA. suggesting that this class of variant may be more refractory to RCA analysis. Despite this, proteomics-based RCA outperformed RCE in the detection of primary mitochondrial disease. It is important to note here that the nature of proteomics as an untargeted approach means that additional analyses can be performed from the same proteomic

data, such as reduced abundance of specific proteins encoded by the gene of interest (**Fig. 1E, F**) and co-dependent proteins in structural modules (**Supplementary Fig. 1B**). This is exemplified in the VC2 (*NDUFS6*) case where despite showing a Complex I abundance of 74%, topographical mapping of Complex I subunit abundances against the cryo-EM structure show specific reduction of the N-module of Complex I, providing strong evidence in supporting disease causation.




Figure 2. Proteomics outperforms clinical respiratory chain enzymology in detection of mitochondrial disorders A – (left) Summary of the RCE results in fibroblasts according to the Bernier criteria³¹. (right) Summary of the RCE results in tissues (skeletal muscle, skm or lymphoblastoid cell line, LCL) according to the Bernier criteria³¹. **B** – Summary of the RCA results from quantitative proteomic data. **C** – Pearson correlation between RCA results and Respiratory Chain Enzymology results for Complexes I, III and IV. **D** – RCA results of OXPHOS complexes from the validation cohort showing the predicted affected complexes for each cell line. CI-V = Complex I-V. Tr. = translation. Middle bar represents mean complex abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. ***** = p<0.001, *** = p<0.01, ** = p<0.05, ns = not significant, p>0.05.

After benchmarking quantitative proteomics and RCA analysis against the validation cohort, we applied our label-free DIA method to six undiagnosed cases where primary fibroblast or skeletal muscle were available for proteomic analysis.

UDP1 (*MT-ATP6*)

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

UDP1 (MT-ATP6) was a four-year-old child who had intrauterine growth retardation, hypotonia, microcephaly, global developmental delay, left ventricular noncompaction and Wolff-Parkinson-White syndrome. Biochemically there was a marginal elevation of blood lactate (2.8 mmol/L; normal range 0.7 - 2.0) and 3methylglutaconic aciduria. Missense variants identified were MT-ATP6 [NC 012920.1(*MT-ATP6*):m.8672T>C;p.(Leu49Pro)], a de novo variant with 81% heteroplasmy in blood, and ATAD3A (heterozygous c.683C>T;p.Thr228Met) from WES plus mtDNA sequencing from blood and both classified as a VUS. Clinical RCE assays typically do not include Complex V activity and proteomics was sought to provide functional evidence. Despite proteomic RCA analysis showing no reduction in abundance of Complex V (104% relative to controls), there was a reduction in the number of Complex V subunits identified from 13 to 10 compared to the diagnosed MT-ATP6 patient as well as other cases in the same batch (Fig. 3A and Supplementary Fig. 4). The Complex V subunits that are not detected in UDP1 (MT-ATP6) but are detected in VC20 (MT-ATP6) are ATP5IF1, the ATPase inhibitor, and ATP5MD (ATP5MK/DAPIT) and ATP5MPL (ATP5MJ/MP68/6.8PL), which like ATP6, are incorporated at a late stage in the assembly of Complex V^{36, 38}. The latter suggests a specific turnover of late stage assembled subunits of Complex V below the limit of detection of proteomics in the proband, which contributes to the unchanged Complex V levels seen in the RCA of UDP1 (MT-ATP6). We processed the same data using q-value sparse run-wise imputation in the Spectronaut® that allows for peptides that were identified in one sample to be imputed at the limit of detection in samples where they were not detected. This allowed us to estimate the fold changes of ATP6 (MT-ATP6) and ATP5MPL proteins in UDP1 (MT-ATP6) and correlate their reduced levels with VC20 (MT-ATP6) as well as confirming unchanged levels of ATAD3A (Fig. 3B). Another data analysis strategy we explored for UDP1 (MT-ATP6) was the use of an in-silico library-free analysis including the protein sequence of the ATAD3A variant p.Thr228Met. As expected, the peptide containing the methionine at position 228 was only detected in the patient (**Fig. 3C**) and present at ~43% of the abundance relative to the canonical peptide expressed from the other allele (**Supplementary Fig. 5A**). Taken together, these results suggest that the *MT-ATP6* p.Leu49Pro variant is the likely diagnosis for this case.

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

The lack of a Complex V defect in proteomics RCA analysis of both MT-ATP6 cases (VC20 and UDP1) prompted us to analyse additional patients with known pathogenic variants affecting Complex V. Supporting cohort probands SC1 and SC2 were two unrelated infants presenting with lactic acidosis, cardiac abnormalities (persistent patent ductus arteriosus, ventriculo-septal defect and cardiomyopathy), mild dysmorphic facial features, hypospadias, hyperammonaemia and 3-methyl-glutaconic aciduria. Targeted gene sequencing based on this phenotype identified in both individuals a homozygous intronic founder variant NM 017866.6(TMEM70):c.317-2A>G classified as Class 5/pathogenic, with several patients previously reported³⁹⁻⁴³. Skeletal muscle samples were available for both cases and compared against three unrelated individuals using the library-free DIA approach. Whole muscle proteomic analyses showed reduction of several Complex V subunits in SC1 and SC2 respectively (Fig. 3D and E). RCA analyses quantified the relative abundance of Complex V at 19% and 20% (Fig. 3F and G). demonstrating that defects in Complex V can be detected using RCA analysis. TMEM70 has also been implicated in Complex I assembly^{44, 45}, although no defects in Complex I abundance were noted in these muscle samples.




Figure 3. Proteomics supports the diagnosis of patients with suspected mitochondrial disorders. A– Relative Complex Abundance (RCA) of Complex V subunits in undiagnosed patient UDP1 (*MT-ATP6*) and diagnosed VC20 (*MT-ATP6*) patient. Middle bar represents mean complex abundance. Upper and

346

lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. ns = not significant, p>0.05. **B** - Correlation between log₂ fold-changes from whole-cell proteins from run-wise imputed data between undiagnosed patient UDP1 (MT-ATP6) and diagnosed patient VC20 (MT-ATP6) harbouring mutations in MT-ATP6 and controls showing reduced abundance in late assembly proteins, MT-ATP6 and ATP5MPL, for both patients. C - Spectral intensity of the peptide containing the ATAD3A p.Thr228Met variant detected in the UDP1 patient but not in controls. **D** – Volcano plot of whole cell proteins from SC1 (*TMEM70*) whole-cell skeletal muscle compared to controls (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent ± 2-foldchange equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent from a two-sample t-test. E - Volcano plot of whole cell proteins from SC2 (TMEM70) whole-cell skeletal muscle compared to controls (N=3) showing reduced abundance of Complex V subunits (orange dots). Vertical lines represent \pm 2-fold-change equivalent and horizontal lines represent significance p-value \leq 0.05 equivalent from a twosample t-test. F - Relative Complex Abundance (RCA) of OXPHOS subunits in undiagnosed patient SC1 (TMEM70). Middle bar represents mean complex abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, *** = p<0.001, * = p<0.05, ns = not significant, p>0.05. **G** – Relative Complex Abundance (RCA) of OXPHOS subunits in undiagnosed patient SC2 (TMEM70). Middle bar represents mean complex abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, *** = p<0.001, ** = p<0.001, * = p<0.001, ** = H - Volcano plot of whole cell proteins from UDP4 (CCDC47) fibroblasts compared to controls showing reduced abundance of CCDC47. No significant changes to Complex V proteins (orange). Vertical lines represent ± 2-fold-change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent from a two-sample t-test. I - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP4 (CCDC47) fibroblasts compared to controls. * = p<0.05, ns = not significant, p>0.05. **J** – Volcano plot of whole cell proteins from UDP5 (NDUFA10) fibroblasts compared to controls showing reduced abundance of NDUFA10 and other structural subunits of Complex I. Vertical lines represent ± 2-fold-change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue = Complex I subunits. K -Relative Complex Abundance (RCA) of OXPHOS complexes from UDP5 (NDUFA10) fibroblasts compared to controls (N=4) showing isolated Complex I defect. Middle bar represents mean complex abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, * = p<0.05, ns = not significant, p>0.05. L -NDUFA10 and HIBCH protein abundance from two-sample t-test in SC3, a confirmed HIBCH proband and UDP5 (NDUFA10) whole-cell fibroblasts compared to controls showing an approximate half reduction in HIBCH levels in UDP5 (NDUFA10, HIBCH carrier) compared to SC3 and unchanged NDUFA10 levels in SC3. M - Timeline for the rapid proteomics from live fibroblast sample receipt to results for UDP5 (NDUFA10) case achieved in less than five days.

UDP4 (*CCDC47*)

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

UDP4 (*CCDC47*) was born to consanguineous parents, presenting with intrauterine growth restriction, severe failure to thrive, short stature, hypotonia, marked developmental delay, mildly dysmorphic features, severe pruritus woolly hair and increased plasma bile acids (224 μmol/L; normal range <7), Ricketts and decreased mitochondrial CIII activity in liver and muscle⁴⁶. WES performed on DNA extracted from fibroblasts and analysed using a mitochondrial disease gene panel identified single heterozygous missense

variants NM 001358921.2(COQ2):c.460G>C; p.(Glv154Ara) and NM 020312.4(COQ9):c.826C>T p.(Arg276Trp). Suspecting a compound oligogenic mechanism impacting Coenzyme Q biosynthesis, RCA analysis was performed on fibroblast cells. No abundance changes to COQ9 or respiratory chain complexes I-IV were identified, although an abundance of 84% in Complex V was noted (Fig. 3H and I). This reduction was regarded as not biologically significant as no rare variants in Complex V related genes were flagged from sequencing data. Transcriptomic analysis performed in RNA extracted from skeletal muscle showed a reduced abundance of CCDC47 transcript (Supplementary Fig. 5B). Re-analysis of proteomics data was sought to provide functional evidence to support the transcriptomic findings, which confirmed a reduction in the abundance of CCDC47 in primary fibroblasts from imputed data (Fig. 3H). Re-analysis of sequencing data identified а homozygous variant NM 020198.3(CCDC47):c.431C>G;p.(Thr144Asn). SpliceAl predicted (δ score 0.964) the activation of a donor-splice site five nucleotides upstream of this variant, and PCR analysis of the muscle cDNA showed the presence of both the missense transcript and a second shorter one, missing 121 bp from the 3' end of exon 4 resulting in a loss-offunction type transcript p.(Val143Glyfs*15) (Supplementary Fig. 5C). This variant is not observed in the gnomAD population database nor any clinical cases previously but is predicted to be classified as likely pathogenic/Class 4, supported by the observed splicing defect, as well as reduced abundance in CCDC47 transcript and CCDC47 protein levels. CCDC47 has been previously linked to Trichohepatoneurodevelopmental Syndrome⁴⁷ (MIM 618268) which presents an overlapping phenotype to UDP4 (CCDC47). The observed reduction in CCDC47 transcripts due to incorrect splicing is in keeping with previously reported patients, all of whom harbour loss-of-function variants^{47, 48}.

UDP5 (NDUFA10)

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

- 418 UDP5 presented with nystagmus, hypotonia, vomiting and weight loss at 20 weeks of age.
- She had lactic acidosis, concentric left ventricular hypertrophy with 48% ejection fraction,
- 420 T2 hyperintense lesions in the substantia nigra and passed away at 24 weeks of age.
- 421 Targeted exome sequencing analysis flagged candidate variants
- 422 NM 004544.4(NDUFA10):c.914T>C; p.(Leu305Pro) homozygous VUS/Class 3,

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

NM 014362.4(HIBCH):c.891+1G>A, heterozygous likely pathogenic/Class 4 and NM 018292.5(QRSL1):c.22G>C, p.(Glu8Gln) heterozygous VUS/Class 3. Fibroblast proteomics detected NDUFA10 and HIBCH below 2-fold-change (representing >50% reduction) in the patient relative to controls (Fig. 3J and Supplementary Figure 5D). QRSL1 level was slightly increased but not significant, which led us to further investigate NDUFA10 and HIBCH leads. NDUFA10 is a structural subunit of Complex I and additional functional evidence for pathogenicity could be drawn from reduced abundance of other Complex I subunits, with RCA analysis quantifying Complex I abundance at 43% in UDP5 (NDUFA10) compared to controls, meeting the criteria for a major defect (Fig. 3K). We further assessed whether the levels of HIBCH protein were compatible with a carrier (heterozygous) state by analyzing fibroblasts from an unrelated patient (SC3) diagnosed with bi-allelic pathogenic variants: NM 014362.4(*HIBCH*):c.891+1G>A NM 014362.4(HIBCH):c.470G>A; p.(Arg157Gln). Proteomic results show that HIBCH protein in SC3 (HIBCH) is almost two times less abundant than in UDP5 (NDUFA10) (Fig. **3L**, **left panel**) while the levels of NDUFA10 protein were unchanged in SC3 (*HIBCH*), suggesting that a reduction in NDUFA10 is not a secondary defect from a primary HIBCH defect (Fig. 3L right panel). The lack of any decrease in Complex I in SC3 (HIBCH) suggests that the phenotype in UDP5 (NDUFA10) is likely to have arisen from the NDUFA10 variant while the HIBCH variant is expressed as a carrier and further investigation for a second missed variant in HIBCH was not undertaken. UDP5 was the first child of non-consanguineous parents of Māori ethnicity. The mother was 6 weeks pregnant with a second child at the time of analysis and the family sought prenatal genetic testing (PGT). With this in mind, we prioritised sample processing and analysis, and were able to return results in less than 4 days from receipt of fibroblasts (Fig. 3M) with the results sufficient to support the upgrade of the NDUFA10 variant c.914T>C; p.(Leu305Pro) to likely pathogenic/Class 4. This facilitated PGT, which confirmed absence of the NDUFA10 variant, allowing continuation of the pregnancy and delivery of a healthy child who, at the time of writing, is 15-months old.

The rapid turnaround time (TAT) in this case was only possible as fibroblasts from UDP5 were available for analysis at the time of proteomics testing. Establishing and culturing a

new fibroblast line typically takes up to ~2 months and requires a skin biopsy⁴⁹ which is increasingly considered invasive and can potentially delay a diagnosis. We sought to explore the feasibility of rapid proteomics-based testing for suspected mitochondrial disorders using peripheral blood mononuclear cells (PBMCs), which can be readily obtained from whole blood and have been used in various diagnostic functional testing approaches previously. To test the applicability of PBMCs in proteomic testing we first generated a fractionated spectral library and compared it against the fibroblast spectral library and coverage of Mendeliome proteins (**Fig. 4A**). The PBMC library was generated from peptides of 39 normal individuals aged 0-17 years of age and can be used to confidently identify 8,016 gene products, including 52% of known Mendeliome genes²⁷. In comparison, our fibroblast spectral library covers 8,305 genes and 55% of the Mendeliome. We performed a Principal Component Analysis (PCA) of whole-cell proteins in the 37 PBMC samples showing that over 99% of the proteins are tightly clustered at the whole-cell level and over 97% at the mitochondrial level (**Fig. 4B**).

Next, we validated the use of PBMCs against fibroblasts by analysing both sample types from a diagnosed patient with pathogenic variants in *MRPL50* (Twin 2 in ²¹, SC4 and SC5). MRPL50 is a structural subunit of the mitoribosome⁵⁰ and defects in this subunit lead to impaired assembly of the large mitoribosomal subunit (mtLSU)²¹. We performed a correlation of the log₂ fold-change levels of mitochondrial proteins identified in both samples relative to controls which showed reduced abundance of multiple proteins belonging to the mtLSU in both sample types (**Fig. 4C**). RCA quantified the abundance of the mtLSU in 63% and 48% in PBMCs and fibroblasts respectively (**Supplementary Fig. 5E**).




Figure 4. Utility of ultra-rapid proteomics supports the diagnosis of critically ill infants with suspected mitochondrial disorders A – Venn diagram showing the coverage of Mendeliome genes (PanelApp Australia Green and Amber entries, 4,264 genes) in the fibroblast spectral library (55% of

480

Mendeliome list of genes) and PBMC library (52% of Mendeliome list of genes). B - Principal Component Analysis (PCA) of the pilot PBMC normative data (N=36) for whole-cell proteins (top panel) and MitoCarta3.0 proteins (lower panel). C - Scatter plot showing the correlation between PBMC (SC4) and fibroblast (SC5) samples based on log2 fold-changes from whole-cell proteins in a diagnosed patient with variants in MRPL50 relative to controls²¹ showing reduced abundance of the proteins belonging to the large subunits of the mitochondrial ribosome (mtLSU; purple), mtSSU = mitoribosome small subunit (orange). **D** – Volcano plot of whole cell proteins from UDP6 (*NDUFA13*) PBMCs compared to controls (N=5) showing reduced abundance of NDUFA13 (orange dot) and other structural subunits of Complex I. Vertical lines represent \pm 2-fold-change equivalent and horizontal lines represent significance p-value \leq 0.05 equivalent. Blue = Complex I subunits. E - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP6 (NDUFA13) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar represents mean complex abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, * = p<0.05, ns = not significant, p>0.05. **F** – Protein range for NDUFA13 in PBMCs in UDP6 (*NDUFA13*, red dot) and controls (N=5, purple dots) showing standard deviation of -12.2 from the control median. G -Volcano plot of whole cell proteins from UDP7 (NDUFAF6) PBMCs compared to controls (N=5) showing reduced abundance of NDUFS8 and other structural subunits of Complex I. Vertical lines represent \pm 2fold-change equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue = Complex I subunits. H - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP7 (NDUFAF6) PBMCs compared to controls (N=5) showing an isolated Complex I defect. Middle bar represents mean complex abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, ** = p<0.01, ns = not significant, p>0.05. I - Timeline for ultra-rapid proteomics from PBMC sample receipt to results for UDP8 (NDUFS8) case achieved in less than 3 business days. J - Volcano plot of whole cell proteins from UDP7 (NDUFS8) PBMCs compared to controls (N=5) showing reduced abundance of NDUFS8 protein (orange dot) and other structural subunits of Complex I. Vertical lines represent ±2-foldchange equivalent and horizontal lines represent significance p-value ≤ 0.05 equivalent. Blue = Complex I subunits. K - Relative Complex Abundance (RCA) of OXPHOS complexes from UDP8 (NDUFS8) PBMCs compared to controls (N=5) showing isolated Complex I defect. Middle bar represents mean complex abundance. Upper and lower bars represent 95% confidence interval. Significance was calculated from a paired t-test between the individual protein means. **** = p<0.0001, ** = p<0.01, * = p<0.05, ns = not significant, p>0.05. L - Protein range for NDUFS8 in PBMCs in UDP8 (NDUFS8, red dot) and controls (N=5, purple dots) showing standard deviation of -9.3 from the control median.

UDP6 (NDUFA13)

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502 503

504

505

506

507

508

509

510

511

512

513

514

515 516

517

518

519

520

521

522

523

524

UDP6 (*NDUFA13*) presented at 2 years of age with chronic ataxia. She was the first child to non-consanguineous healthy parents from Iran and had a healthy 2-month-old brother. There was no family history of any neurological issues. She presented with chronic, stable ataxia, having been unsteady and falling frequently since she started walking at 14 months of age. She had mild fine motor delay and a tremor. Her social, language, and cognitive development was age appropriate. On examination, UDP6 (*NDUFA13*) had normal growth parameters and was not dysmorphic. She had mild gait ataxia with a broad base. Her tone, power and reflexes were normal in upper and lower limbs bilaterally.

Ophthalmology examination was unremarkable. Magnetic resonance imaging (MRI) of brain showed bilateral symmetrical T2/FLAIR hyperintensity of the cerebral peduncles of the midbrain (and possibly the substantia nigra) and two symmetrical foci of high signal in the dorsal medulla with diffusion-weighted imaging (DWI) restriction. There were no basal ganglia or thalamic abnormalities. This was suggestive of a mitochondrial disorder. Serum blood lactate was elevated 2.4 (RR 1.0-1.8). Other metabolic investigations were normal. Audiology assessments and echocardiogram were normal. At 4 years of age, she has ongoing mild ataxia that improved with physiotherapy and was no longer falling. She has recently had deterioration in her vision and been diagnosed with optic neuropathy. Trio identified exome sequencing compound heterozygous variants NM 015965.7(*NDUFA13*):c.170G>A; p.(Arg57His) likely pathogenic/Class 4 and NM 015965.7(NDUFA13):c.187G>A; p.(Glu63Lys) VUS/Class 3. Proteomics was sought to provide functional evidence for the VUS/Class 3 variant and blood was collected for PBMC isolation as fibroblasts were not available at the time of analysis. Five unrelated PBMCs from age-matched normal donors were used as controls. A volcano plot showed reduction of NDUFA13 protein and several other Complex I subunits in UDP6 (NDUFA13) (Fig. 4D) and RCA quantified the isolated Complex I defect at 47% control satisfying the criteria for a major defect (Fig. 4E). Analysis of the level of the NDUFA13 protein in the proband demonstrated a residual abundance of 39%, which corresponds to greater than 12 standard deviations below the control median (Fig. 4F). Proteomics data were subsequently functional evidence to upgrade used as the NM 015965.7(NDUFA13):c.187G>A;p.(Glu63Lys) variant to likely pathogenic/Class 4.

UDP7 (NDUFAF6)

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541 542

543

544

545

546

547

548

549

550

551

552

553

554

555

UDP7 (*NDUFAF6*) was referred to the study at five months of age with asymmetric early onset growth restriction, central hypotonia, proximal renal tubular dysfunction, macrocytic anaemia, severe exocrine pancreatic insufficiency, liver dysfunction with cholestasis and mild persistent elevated lactate in CSF and blood. MRI showed symmetrical diffusion abnormality involving corticospinal tract, areas of brainstem and medial cerebellar hemisphere. He died at seven months of age due to progressive bulbar dysfunction with a probable clinical diagnosis of Leigh syndrome. Clinical trio WES identified a single

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

pathogenic (Class 5) heterozygous NM 000262.3(NAGA):c.973G>A; p.(Glu325Lys) variant. and variants two in trans in NDUFAF6. frameshift NM 152416.4(NDUFAF6):c.267delT, p.(Tyr323llefs*18) variant and a deep intronic NM 152416.4(NDUFAF6):c.298-768T>C, both classified as VUS/Class 3. PBMCs were the sample of choice due to lower invasiveness and potential for fast turnaround. Whole-cell proteomics identified no changes in the abundance of NAGA protein relative NAGA controls (Fig 4G). encodes the alpha-Nacetylgalactosaminidase, a lysosomal enzyme whose deficiency causes a rare autosomal recessive lysosomal storage disorder. Previous reports of NAGA-deficiency show heterogenous presentations ranging from infantile-onset neuroaxonal dystrophy (Schindler disease type I, MIM 609241) to an adult-onset disorder characterised by angiokeratoma corporis diffusum and mild intellectual impairment (Schindler disease type II, also known as Kanzaki disease MIM 609242)⁵¹. In addition to the proteomic studies, UDP7 (NDUFAF6) did not appear to have clinical features consistent with NAGAdeficiency, and infants with this condition typically develop normally until about a year old. We then turned our investigations to NDUFAF6 (C8orf38) which encodes an assembly factor involved in biogenesis of the core peripheral arm subunit NDUFS8 of Complex I⁵² and has previously been associated with the stability of the ND1 module of Complex I⁵³, ⁵⁴. Previous reported cases of pathogenic variants in *NDUFAF6* present with a range of symptoms, including Leigh syndrome and the Acadian variant of Fanconi syndrome 5 (proximal renal tubular dysfunction) (FRTS5, MIM 618913)⁵³⁻⁵⁷. UDP7 (NDUFAF6) had clinical features consistent with Leigh syndrome, and while the aetiology of his liver dysfunction and severe exocrine pancreatic insufficiency was somewhat less clear, both would broadly fit with a mitochondrial cytopathy noting Complex I deficiencies often do not correlate perfectly with а single clinical subdivision. The NM 152416.4(NDUFAF6):c.298-768T>C variant has been reported as likely pathogenic previously, specifically in relation to the FRTS5 phenotype⁵⁶. A volcano plot from wholecell PBMC proteomics data showed reduction in the abundance of several subunits of Complex I in UDP7 (NDUFAF6), including NDUFS8, (Fig. 4G) with RCA analysis quantifying the isolated Complex I defect with a major defect of 34% relative to controls (Fig. 4H). Functional proteomic data and phenotype match support NDUFAF6 as being

the causative gene for this clinical case, and the VUS/Class 3 variants are in the process of re-curation at the time of writing.

UDP8 (NDUFS8)

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

UDP8 (NDUFS8) was a neonate admitted to hospital presenting with persistent lactic acidemia, hypertrophic cardiomyopathy, left pulmonary artery stenosis, thickened pulmonary valve, hypotonia and microcephaly with progressive deterioration from 4 weeks of age, succumbing at 5 weeks of age. Brain MRI showed abnormalities in the corpus callosum and diffuse increased signal throughout the supratentorial white matter with small foci of gliosis in the peritrigonal regions. Ultra-rapid trio WGS identified a homozygous intronic variant NM 002496.4(NDUFS8):c.501+5G>A with biparental inheritance. Due to the critical deteriorating condition, blood was collected from the proband and subjected to ultra-rapid proteomics. Five unrelated age-matched controls were used for comparison and the complete analysis was performed with a 54-hour turnaround time (TAT) from PBMC sample reception to the reporting of results to the clinical team (Fig. 4I). Whole-cell proteomic analysis of PBMCs showed significant reduction of several Complex I subunits, including NDUFS8 (Fig. 4J) and RCA analysis showed an isolated Complex I defect with a major defect of 22% relative to controls (Fig. **4K**). Residual abundance of the NDUFS8 protein in the proband was quantified at 20%. representing over 9 standard deviations below the control median (Fig. 4L). The strong phenotype match together with functional evidence from proteomics support disease causation due to variants in NDUFS8 and leading to variant upgrade to likely pathogenic/Class 4.

Discussion

The estimated prevalence of rare disease in the population is in the range of 3.5-6%, equivalent to 263-446 million individuals worldwide⁵⁸. There are over 7,000 different rare diseases known, with a current diagnostic yield of ~35-70% from WES or WGS¹⁻⁵. Mitochondrial disease is a group of rare diseases caused by variants in over 300 known genes^{6, 16}, where RCE has been historically performed to confirm a specific OXPHOS defect in the functional validation of variant pathogenicity¹⁶.

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

We have previously used an approach we term relative complex abundance (RCA) where proteomics data are used to quantify the residual abundance of OXPHOS complexes in clinical samples from individuals suspected of mitochondrial disease. We have shown that RCA acts as an effective proxy for clinically accredited RCE, including when appropriate samples have not been available 20-22, 24, 25, 59-61. In an RCA analysis, the abundance of a complex in a sample is calculated from the mean of each individual subunit abundance detected by more than two peptides across each complex. The power of RCA analysis relies on the quantification of multiple peptides per protein in a complex with a high degree of subunit stability co-dependence, as we and others have previously shown for Complex I, III, IV, the mitoribosome 11, 17, 20-22, 25, 59, 60, 62, 63 and non-mitochondrial complexes such as the exocyst and nuclear pore complexes^{64, 65}. RCE, on the other hand, typically relies on enzyme rate estimates determined in several replicates of patient samples and compared against age-matched controls. In some instances, we have found RCA demonstrated higher sensitivity by detecting a specific OXPHOS defect where RCE was inconclusive^{20, 22}. RCA can also show higher specificity for use in functional validation of variant pathogenicity by detecting reduction of specific parts of the complex (e.g. loss of subunits in the catalytic Complex I N-module in VC1-NDUFAF2 and VC2-NDUFS6), implicating only the 10 N-module subunits as candidate genes compared with loss of Complex I RCE potentially being caused by variants in any of more than 50 genes encoding Complex I subunits and assembly factors^{26, 66}. In other cases, some variants encoded by the mtDNA resulted in no defect on RCA analysis despite over 70% and 90% heteroplasmy levels in fibroblasts. This suggests that some mtDNA variants can be refractive to RCA analysis due to an enzymatic and not a structural defect, where RCE might be an appropriate test to provide functional evidence. In terms of variant type, mitochondrial DNA variants account for only 0.54% of rare diseases while autosomal recessive variants account for over 41%67 and are more likely to result in a loss-offunction protein⁶⁸, which can be detected via quantitative proteomics.

RCE is typically performed on a tissue biopsy sample (e.g. skeletal muscle, liver) or primary cultured cells (e.g. fibroblasts). Establishing and growing primary fibroblasts from

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

skin biopsies to a sufficient volume of cells for RCE analysis involves weeks to months of cell culture⁴⁹, and, in some cases, tissue specificity results in only mild or undetectable defects as measured by RCE¹⁰. Here we have demonstrated the feasibility of using PBMCs in diagnostic proteomics testing. In our hands, sufficient PBMCs for these analyses can be readily obtained from as a little as 1 ml of whole blood and the process from PBMC isolation to data acquisition performed in less than 48 hours. Together these properties and the results presented in this study demonstrate that PBMCs can be combined with our ultra-rapid proteomics pipeline for functional validation of variants causing defects in the mitochondrial OXPHOS system and the mitoribosome.

The untargeted nature of quantitative proteomics also allows this technique to be applied beyond mitochondrial disease, as we have shown here for a mitochondrial disease phenocopy (UDP4; CCDC47) and elsewhere for nuclear pore, neuronal exocytic vesicle trafficking and rigid spine disorders^{64, 65, 69}. Over 50% of known disease-associated genes²⁷ are routinely detected by our quantitative proteomics pipeline in PBMCs or fibroblasts, and over 45% of all disease genes listed in OMIM are part of a protein complex¹⁶. This means that pathogenic variants in one of these genes can lead to reduction of the protein of interest, which in some cases will result in downstream complex reduction as an additional layer of functional evidence to support variant upgrade. In terms of variant type, we show that quantitative proteomics can provide functional evidence for a wide range of genetic variants including CNV⁶², splice site and deep intronic^{20, 22}, and missense variants²¹. Missense variants are the most common type of variant accounting for 60% of pathogenic variants associated with autosomal recessive disorders¹⁸ and are usually refractory to transcriptomic analysis. For some cases, proteomics can also provide supportive functional evidence supportive when the protein encoded by the candidate gene is not detectable, either due to protein abundance being below the limit of detection or for genes encoding tRNAs, as seen in VC22 (MT-TK), further expanding the potential application of proteomics in rare disease diagnosis.

A genomics-first approach to rare disease diagnosis has markedly increased diagnostic rates and, in the case of rapid and ultra-rapid genomic testing, shortened diagnostic

odysseys to days instead of months^{65, 70-72}. In the case of mitochondrial and many other rare diseases, diagnoses are often now achieved using just a blood sample, sparing many patients from an invasive biopsy of muscle or other tissues. As a result, diagnostic centres such as ours now receive a third or less of the number of samples for RCE testing than received 10 years ago. This provides an incentive for untargeted functional tests, such as RNA sequencing and proteomics, that could be financially viable and widely available in a pathology-certified context.

This study also highlights the limitations of quantitative proteomics in detecting abundance changes in variants leading to catalytic defects and some mtDNA-encoded variants in fibroblasts. Moreover, the detection of proteins is related to the limit of mass-spectrometry detection as determined by the liquid chromatography, instrumentation, and data acquisition methods used. However, recent advances in massspectrometry instrumentation including development of the asymmetric track lossless (Astral) analyzer offer further improvements in sensitivity and greatly reduced run times⁷³. Quantitative proteomics thus offers a further paradigm shift by providing functional evidence for variants in thousands of genes in a single test. This driver will facilitate the translation of proteomics testing for rare diseases into certified pathology laboratories. Clinically delivered proteomics can potentially replace hundreds of tests targeted to specific diseases, which are usually restricted to research settings and carry less weight in the upgrade of variants. Our study also demonstrates that proteomics can be delivered alongside ultra-rapid genomic sequencing approaches to provide functional data in a clinically relevant timeline.

Materials and Methods

Ethics statement

680

681

682

683

684

685

686

687

688 689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

This study was conducted in accordance with the revised Declaration of Helsinki and following the Australian National Health and Medical Research Council statement of ethical conduct in research involving humans. Samples were obtained after receiving written, informed consent for diagnostic or research investigations from the respective responsible human ethics institutional review boards. HREC/RCH/34228, HREC/RCH/34183, HREC/89419/RCHM-2022 and HREC/82160/RCHM-2022 were

- approved by the Royal Children's Hospital, Melbourne, Ethics in Human Research
- 713 Committee. HREC/16/MH/251 was approved by the Melbourne Hospital Ethics in Human
- Research Committee. The REC reference 2002/205 by the Newcastle and North
- 715 Tyneside Local Research Ethics Committee.
 - Genomic investigations

- Genomic investigations resulting in diagnosis of patients within the validation cohort (VC)
- are described in the publications indicated by PMID within **Supplementary Table 1**, with
- 720 the exceptions of VC13 (SDHAF1), VC15 (UQCRC2) and VC24 (FARS2) which are as
- 721 follows; Individual VC13 (SDHAF1) underwent clinical singleton WES through Baylor
- Genetics as previously described⁷⁴. For individual VC15 (UQCRC2), homozygosity
- 723 mapping from Illumina HumanCytoSNP-12 v2.1 array data identified substantial long
- 724 contiguous stretches of homozygosity (LCSH) accounting for ~3.7% of the genome. Due
- to the observed complex III RCE defect in this patient, candidate gene sequencing of
- exons using genomic DNA through PCR and sanger sequencing was performed on
- 727 complex III-related genes *UQCC1* and *UQCRC2* which lay within these regions of LCSH
- 728 (primers available upon request). Blood DNA for individual VC24 (FARS2) underwent
- 729 clinical singleton WES testing through the Victorian Clinical Genetics Service (VCGS) as
- 730 previously described⁷⁵. mtDNAseq was also used to quantify mtDNA variant
- heteroplasmy levels for individuals VC6 (MT-ND1) and VC12 (MT-ND5) as previously
- described⁷⁵. Individuals within the undiagnosed patient (UDP) cohort were investigated
- 733 as follow: blood DNA from UDP1 (*MT-ATP6*) underwent WES with mitochondrial DNA
- 734 sequencing (mtDNAseq) as part of the Australian Genomics Mitochondrial Flagship as
- described⁷⁵. For individual UDP4 (*CCDC47*), sequencing and analysis was performed as
- 736 previously described²⁵. Individual UDP5 (*NDUFA10*) had the Comprehensive Metabolism
- 737 Panel performed by Blueprint Genetics. Individuals UDP6 (NDUFA13) and UDP7
- 738 (NDUFAF6) both underwent clinical trio WES through the Victorian Clinical Genetics
- 739 Service (VCGS)⁷⁵. UDP8 (*NDUFS8*) had acute-care rapid trio WGS and analysis at the
- 740 VCGS as previously published⁶⁵.
- 742 Respiratory chain enzymology
- Respiratory chain enzyme activities in fibroblasts and skeletal muscle were measured by
- spectrophotometry as described¹⁰. Complex I (CI) was measured as rotenone-sensitive
- 745 NADH:coenzyme Q₁ oxidoreductase, Complex II (CII) as succinate:coenzyme Q₁
- 746 oxidoreductase. Complex III (CIII) as decylbenzylguinol:cytochrome c reductase, and
- 747 Complex IV (CIV) as cytochrome c oxidase. Citrate synthase (CS) was measured as

- production of coenzyme A (CoA.SH) from oxaloacetate using the thiol reagent 5,5'-dithio-
- bis-(2-nitobenzoic acid). Enzyme activities were calculated as initial rates (CI, CII, and
- 750 CS) or as first-order rate constants (CIII and CIV)¹⁰.
- 752 Cell Culture Conditions

- 753 Fibroblast and HEK293T cell lines were cultured in Dulbecco's Modified Eagle Medium
- 754 (DMEM) High Glucose, Sodium Pyruvate and Glutamine (Sigma-Aldrich) supplemented
- 755 with 10% (v/v) Fetal Calf Serum (FCS; CellSera), 100 U/mL Penicillin-Streptomycin
- 756 (Gibco) and 50 μg/mL Uridine. Cells were maintained at 37°C with 5% CO2.
- 758 Generation of knockout lines
- 759 The NDUFS2^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding the
- 760 guide RNA 5'-TGAGGGCTTTGTGCGGCTTCCGG-3' cloned into the pSpCas9-2A-GFP
- vector ²⁶. The CRISPR was transfected into HEK293T cells and single cells were obtained
- by Fluorescence-activated cell sorting at the Monash Flow Cytometry Platform (Flowcore).
- 763 Singe cell populations were screened by loss of cell viability on galactose-containing
- DMEM and subsequently validated by the loss of protein by western blotting and indel
- sequencing, which identified two deletions c.[18 36del] and c.[17 42del] Supplementary
- table 1). The UQCRC2^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding
- 767 the guide RNA 5'-CACCGGTACTTACACATCACCCGC designed using the
- 768 CHOPCHOP tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously
- described²⁶. The plasmids were validated by sequencing, and then transfected into target
- 770 cell lines using Lipofectamine™ 3000 Transfection Reagent (Thermo Fischer Scientific)
- according to manufacturer's guidelines. Single cells expressing GFP were isolated on a
- 772 FACS Aria Fusion (BD Biosciences) cell sorter and clonal populations were subsequently
- screened for relevant gene knockouts using SDS-PAGE and immunoblotting and indel
- sequencing, which identified two deletions c.[9141_9199del] and [9146_9167del]
- (Supplementary table 1). The SURF1^{KO} cell line was generated using a CRISPIR/Cas9
- system with the HEK293T parental cell line. Two guide RNAs targeting the 5'UTR and
- exon 2 regions of *SURF1* were cloned into individual pSpCas9-2A-GFP vectors (Addgene,
- plasmid 48138 ¹⁸). Both constructs were transfected simultaneously into HEK293T cells
- using Lipofectamine 3000 (Thermo Fisher Scientific), according to the manufacturer's
- 780 instructions. Verification of successful HEK293T SURF1^{KO} was performed via three
- 781 primer screening PCR were used to amplify incorporated indels via PCR and by SDS-
- 782 PAGE immunoblotting. The product of external Primers (outside the double CRISPR)
- 783 target sites) underwent M13 primer Sanger Sequencing of alleles, using the Topo[™] TA

Cloning Kit (Thermo Fisher Scientific) as per the manufacturer's instructions. Sequencing identified two deletions [c.18_219del] and [c.18_221delinCG] (Supplementary table 1). The ATP5PD^{KO} cell line was generated using a CRISPR/Cas9 plasmid encoding the guide RNA 5'-CACCGCCTTTCCTTGTGGGCAGGT designed using the CHOPCHOP tool and subcloned into pSpCas9(BB)-2A-GFP vector as previously described²⁶. The plasmids were validated by sequencing, and then transfected into target cell lines using Lipofectamine[™] 3000 Transfection Reagent (Thermo Fischer Scientific) according to manufacturer's guidelines. Single cells expressing GFP were isolated on a FACS Aria Fusion (BD Biosciences) cell sorter and clonal populations were subsequently screened for relevant gene knockouts using indel sequencing, which identified a single deletion c.[33481insT] (Supplementary table 1).

PBMC isolation from whole blood

Neonatal blood samples were collected from healthy neonates following routine intramuscular administration of Vitamin K. For older infants and children ages 30 days to 18 years, venous blood samples were obtained from hospital outpatients undergoing minor elective day surgery. An outline of the study protocol and complete detail of participant recruitment, inclusion and exclusion criteria and sample collection are described in our previously published HAPPI Kids study protocol⁷⁶. PBMCs were isolated from fresh blood samples of the 37 HAPPI Kids controls using Ficoll®-Paque Plus (GE Healthcare Life Sciences) according to the instructions of the manufacturer with manual removal of the PBMC layer using a Pasteur pipette. For the UDP6 (*NDUFA13*), UDP7 (*NDUFAF6*) and UDP8 (*NDUFS8*) probands, PBMC isolation using Ficoll®-Paque Plus was performed in SepMateTM tubes (STEMCELL Technologies), based on manufacturer's protocols with moderate braking applied for both washes, and a reduction in centrifugation speed and duration to 200 *g* for five minutes for the second wash.

Data-Independent Acquisition Mass Spectrometry of Fibroblast, HEK293T and PBMCs

Cohorts and Data Analysis

Spectral Library Sample Preparation

A HEK293T spectral library was generated from both whole cell and mitochondrial HEK293T samples to search data-independent acquisition (DIA) HEK293T knockout cell lines. A total of 100 µg of mitochondrial sample isolated from wildtype HEK293T cells underwent carbonate extraction at pH 11.5 to separate soluble and integral mitochondrial proteins, as previously described⁷⁷. The resulting pellet and supernatant samples, as well

821 822

823

824

825 826

827

828

829

830

831

832

833 834

835

836 837

838

839

840 841

842

843

844

845

846

847 848

849

850

851852

853

854

855

as 25 µg whole cell HEK293T sample, were solubilized in lysis buffer for a final composition of 5% SDS and 50 mM Triethylammonium bicarbonate (TEAB) pH 8.5. The lysed whole cell, mitochondrial pellet and supernatant samples were processed using Strap[™] Micro Spin Columns (ProtiFi) according to the manufacturer's instructions, where samples were reduced with 40 mM 2-chloroacetamide (CAA, Sigma) and alkylated with 10 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; BondBreaker, Thermo Fischer Scientific). Isolated proteins were digested at 1:25 trypsin to protein ratio at 37°C overnight and eluted peptides were dried down using a CentriVap Benchtop Vacuum Concentrator (Labconco). Fibroblasts and PBMCs spectral libraries were generating from whole cell samples of either five healthy fibroblast controls or PBMC pellets isolated from 39 healthy individuals ranging from 0-17 years old. Fibroblast or PBMC pellets were solubilized 5% SDS and 50 mM TEAB pH 8.5, and total protein determined by Pierce bicinchoninic acid (BCA) Protein Assay Kit (Thermo Fisher Scientific). A total of 25 ug for each control was processed using the S-Trap™ Micro Spin Columns (ProtiFi), as described above. Peptides from HEK293T, fibroblast and PBMC samples were reconstituted in 0.5% formic acid (FA) for fractionation. Fibroblast and PBMC control samples were pooled upon reconstitution to create a single fibroblast, HEK293T and PBMC peptide mixture and loaded onto a strong cation exchange (Empore Cation Exchange-SR, Supelco Analytical) stage-tips made as described⁷⁸. Stage tips were washed with 20% acetonitrile (ACN) and 0.5% FA and eluted over seven fractions of increasing concentrations of ammonium acetate (45-300 mM), 20% ACN and 0.5% FA for whole cell fibroblasts, PBMC and

HEK293T samples. HEK293T mitochondrial and supernatant samples, were collected over five fractions. All samples underwent a final elution with 5% ammonium hydroxide

and 80% ACN, followed by concentration using a CentriVap Benchtop Vacuum

Concentrator (Labconoco). Fractions were desalted on SDB-XC (poly(styrene-divinyl-

benzene); Supelco Analytical) stage tips made in-house as previously described⁷⁸.

Spectral Library Mass Spectrometry Data Dependent Acquisition

Fractions were reconstituted in 0.1% trifluoracetic acid (TFA) and 2% ACN and each library was analyzed by liquid chromatography (LC)-tandem mass spectrometry (MS/MS) on an Orbitrap Eclipse Mass Spectrometer (Thermo Fischer Scientific) operating on DDA mode over a 125-minute gradient. Tryptic peptides were loaded onto an Acclaim Pepmap nano-trap column (Dinoex-C18, 100 Å, 75 µm × 2 cm) at an isocratic flow of 5 µl/min of 2% ACN and 0.1% FA for six minutes before switching with an Acclaim Pepmap RSLC analytical column (Dinoex-C18, 100 Å, 75 µm × 50 cm). The separation of peptides was

performing using a nonlinear 125-minute gradient of solvent A (5% dimethyl sulphoxide (DMSO), 0.1% FA) and solvent B (5% DMSO, 100% ACN, 0.1% FA). The flow gradient was (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-40% solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent B, (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes before the next injection. Briefly, the data was collected using positive polarity with a MS1 scan range of 375-1500 m/z and resolution set to 120,000. Other MS1 instrument parameters include: ACG target of 4e5, maximum injection time of 50 ms and Isolation window of 1.6. MS2 instrument parameters include: scan range of 150-2000 m/z, resolution of 15,000, HCD collision energy of 30%, ACG target of 5e3, maximum injection time of 22 ns and dynamic exclusion of 30 s.

Sample Preparation of HEK293T, PBMC and Fibroblast Cell Lines

Whole cell pellets of HEK293T cells, PBMCs and fibroblasts were collected and washed twice with PBS before resuspension in 5% SDS, 50 mM tetraethylammonium bromide (TEAB) pH 8.5 buffer and 125 U of benzonase per ml (Sigma-Aldrich). Skeletal muscle samples were solubilized with a probe sonicator with 30% amplitude in 5% SDS, 50 mM TEAB pH 8.5 buffer on ice with a cycle of 10 seconds on 10 seconds off for 1 minute and clarified at 16,000 x q for 5 minutes. Protein concentration was performed with Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and 25 µg of each sample was aliquoted in triplicates for patients and singlicate for individual controls (N=3-5). Samples were processed using S-trap[™] micro spin columns (ProtiFi) according to the manufacturer's instructions. Proteins were digested with trypsin (Thermo Fisher Scientific) at 1:10 trypsin to protein ratio. Peptides were dried down using a CentriVap Benchtop Vacuum Concentrator (Labconco) and reconstituted in 45 µL 2% ACN, 0.1% trifluoroacetic acid (TFA) and 2 µL injected for liquid chromatography tandem mass spectrometry (LC-MS/MS). Samples were analyzed for 125 minutes (HEK293T) or 95 minutes (Fibroblasts, skeletal muscle, PBMCs) on an Orbitrap Eclipse mass spectrometer (Thermo Fisher Scientific) operating in DIA mode.

Mass Spectrometry Data Independent Acquisition

Peptides were reconstituted in 45 μ L of 2% ACN and 0.1% TFA and 2 μ l was injected into an Orbitrap Eclipse mass spectrometer (Thermo Fischer Scientific) for LC-MS/MS analysis equipped with trap and analytical columns described above. All samples were analysed with the mass spectrometer operating in DIA mode. The separation of peptides was performed using a nonlinear gradient of solvent A and solvent B across 125-minutes

for HEK293T knockout cell lines, and 95-minutes for all other sample types (fibroblasts, PBMCs and skeletal muscle). Briefly, for the 125-minute method, the flow gradient was (i) 0-6 min at 3% solvent B, (ii) 6-95 min at 3-23% solvent B, (iii) 95-105 min at 23-40% solvent B, (iv) 105-110 min at 40-80% solvent B, (v) 110-115 min at 80-80% solvent B, (vi) 115-116 min at 80-3% solvent B and equilibrated at 3% solvent B for 10 minutes before the next injection. The data was collected using positive polarity with a MS1 scan range of 350-1200 m/z at a resolution of 120,000. Other MS1 instrument parameters include: ACG target of 1e6, maximum injection time of 50 ms, Isolation window of 24 with 1 m/z overlap. For MS2 parameters, the scan range was 200-2000 m/z at 15,000 resolution, HCD collision energy of 30%, AGC target of 1e6 and maximum injection time of 22 ms. For the 95-minute method, the flow gradient was (i) 0-6 min at 3% solvent B, (ii) 6-7 min at 3-4% solvent B, (iii) 7-82 min at 4-25% solvent B, (iv) 82-86 min at 25-40% solvent B, (v) 86-87 min at 40-80% solvent B, (vi) 87-90 min at 80-80% solvent B, (vii) 90-91 min at 80-3% solvent B and equilibrated at 3% solvent B for 5 minutes before the next injection. Instrument parameters were consistent with those used in the 125-minute method described above, with changes made to the following parameters: MS1 scan range of 350-1400 m/z, MS1 maximum injection time of 45 ms, Isolation window of 13.7 and MS2 ACG target of 5e5.

Proteomic data search

892 893

894

895

896

897 898

899

900 901

902

903

904 905

906

907

908

909

910911

912913

914

915916

917

918

919920

921

922923

924

925926

927

For spectral library, raw files were imported into Spectronaut^{®79} (v.15.2.210819.50606 for HEK293T library, v.14.8.201029.4778 for fibroblasts library, v. 16.0.220606.53000 for PBMCs library) and the three libraries were generated using the 'Pulsar' option with default BGS Factory settings, searching against Uniprot human database containing reviewed canonical and isoforms sequences (42,386 entries). The resulting HEK293T library contained 194,270 precursors, the fibroblast library contained 131,627 precursors, and the PBMC library contained 148,522 precursors. For DIA samples, raw files were imported into Spectronaut® and searched against the libraries generated above. Default BGS Factory search parameters were used with changes made to exclude single hit proteins, no selection of 'Major Group Top N' and 'Minor Group Top N' and data filtering setting set to 'Q-value' or 'Q-value sparse' with 'run-wise imputation' as an imputing strategy. 'Q-value' datasets (unimputed) were used for generation of RCA values while 'Q-value sparse' with 'run-wise imputation' datasets were used to generate heatmaps and correlation plots to reduce missing values for visualization, and in volcano plots for VC and KC cohorts or when the protein of interest was not well detected. UDP1 (MT-ATP6) data was also searched using BGS Factory direct DIA settings (library free) with changes as above with inclusion of the p.Met228 variant peptide fasta file in the protein database search. SC1 and SC2 (*TMEM70*) skeletal muscle were searched with default BGS Factory direct DIA settings with changes as above.

Protein filtering and clean up

928 929

930

931932

933

934

935

936937

938

939 940

941

942

943

944 945

946

947

948 949

950

951 952

953954

955

956

957

958959

960

961 962

963

Proteins were filtered in each cohort to ensure that the data was of high quality and with a minimal amount of missing data for analysis. Proteins within the validation cohort (VC) were filtered out if identified by a single peptide in all controls or proband samples, maintaining proteins that were identified by >2 peptides in both groups. Proteins were then filtered to least three or more valid values for the controls and at least two or more valid values for the proband samples. For the knockout cohort (KC), proteins were filtered out if identified by a single peptide in all controls and proband samples. Proteins were then filtered to at least two valid values for the controls and at least two valid values for the knockout sample. For the undiagnosed proband cohort (UDP), proteins were filtered out if identified by a single peptide in all controls or proband samples. Proteins were then filtered for 70% valid values for the controls due to the different number of controls per batch and 70% valid values for the proband samples. For the supporting cohort (SC), samples SC1, SC2, SC3 and SC5 proteins were filtered out if identified by a single peptide in all controls or proband samples. Proteins were then filtered for 70% valid values for the controls and 70% valid values for the proband samples. Sample SC4 had no filtering completed as this was a previously published dataset²¹ and the data was unlogged and complex subunit gene names manually updated to match the current MitoCarta3.0 naming convention for Complex V subunits. For the 36 PBMC control samples (SC6-41), proteins were filtered out if they were identified by a single peptide across all 36 samples and further filtered for at least 70% valid values.

Relative Complex Abundance Plots

Relative complex abundance (RCA) plots were generated for all VC, KC, SC and UDP cohorts and plots can be viewed within the RDMS Explorer platform. All samples underwent mitochondrial normalization where the mean of the mitochondrial proteins for each specific sample was determined using the average of all control mitochondrial proteins or proband mitochondrial proteins and then used as a normalization factor for each group and applied to each sample. To develop the RCA plots, the average of the proband and controls was determined and then transformed to log10. The difference between the log10 of the proband and controls was determined and then unlogged. Statistical difference between the control and proband complex subunits was determined

using a paired t-test and summary statistics including mean and the error bars indicating standard deviation were determined for each complex and the graph plotted within R (v.4.3.2). Complex subunits were determined using curated annotations from MitoCarta3.0²⁸. For Supplementary Fig. A, relative mitochondrial abundance from MitoCarta3.0 '+' entries were generated as above without the mitochondrial normalization step. For Supplementary Fig. B, control mitochondrial abundance plots were generated using log2 abundances from MitoCarta3.0 '+' entries for each batch and significance performed with an ANOVA test.

Protein range graphs

964 965

966

967968

969

970971

972973

974

975976

977

978

979 980

981

982 983

984

985

986

987

988 989

990

991 992

993

994

999

Protein range graphs were developed using an in-house R script. The median of the protein of interest in control samples is calculated as well as the median of the proband replicates. The log2 fold-change is calculated between the proband and control and converted to percentage for the proband as the abundance relative to the control median for plotting. The range of the controls is also displayed as the abundance relative to the control median. The log2 abundance per standard deviation (SD) is rounded to one decimal place with the top axis SD present to determine how many standard deviations the protein is from the control median.

Volcano and Correlation plots

The peptide and valid value cleaned matrices for all samples were annotated with MitoCarta3.0²⁸ entries in Perseus⁸⁰. All analyses were performed in Perseus v 1.6.14.0. Volcano plots were visualized using scatter plot function from a two-sample t-test using p-value threshold of 0.05 in Perseus. For the correlation plots (Fig 3B, Supplementary Fig.2B), proteomic data searched with q-value sparse with run-wise imputation settings were correlated via gene name using gene name entries and the logFCs in R and plotted using scatter plot function in Perseus. For Fig. 4C, previously published data from MRPL50 Fibroblasts²¹ were correlated with MRPL50 PBMCs using gene name entries and the logFCs in R and plotted using scatter plot function in Perseus.

RDMS Explorer Website.

RDMS 995 ΑII the code used develop the Explorer website to (https://rdmassspec.shinyapps.io/RDMSExplorer/) and in-house analysis performed in R 996 found (https://doi.org/10.5281/zenodo.12883602) 997 can be at and 998 (https://github.com/nicaruana/rdms_oxphos).

Heatmaps and Venn diagrams

1000

1001

1002

1003 1004

1005

1006 1007

1008 1009

1010

1011

1012

10131014

1015

1016

1017

1018 1019

1020 1021

1026

For heatmaps output matrices searched with q-value sparse run-wise imputation settings Spectronaut runs were log₂ transformed and a two-sided t-test using p-value for truncation was performed in Perseus for each cell line against their respective batch controls. The Morpheus software was used for heatmap visualization (https://software.broadinstitute.org/morpheus). For Supplementary Fig. 1A, proteins were manually annotated based on MitoCarta3.0 as 'assembly factor' or 'complex I-V' and subset for visualization in Morpheus using the following parameters metric 'one minus Pearson correlation', linkage method 'average', cluster 'rows' and group columns by 'complex/assembly factor'. P-value results from t-test statistical analysis were used to visualize the significance of each data point by overlaying the p-value matrix onto the ttest matrix in Morpheus and using the option size by 'p-value matrix' size minimum '0' and maximum '1.301' (p-value<0.05). For the correlation heatmap plot (Supplementary Fig. 2A), hierarchical clustering was used with the following parameters in Morpheus: metric 'one minus Pearson correlation', linkage method 'average' and cluster 'columns'. Topographical heatmaps (Supplementary Fig. 1B) were generated from log₂-transformed fold-change from t-test in Pymol using the PDB structures (CI: 5LDW, CII: 1ZOY, CIII: 1BGY, CIV: 5Z62, CV: 7AJD) as previously described²⁶. Venn diagrams were generated with DeepVenn⁸¹ from gene names. Green (diagnostic-grade) and amber (borderline diagnostic-grade) lists for mitochondrial disease (v.0.787) and Mendeliome gene lists (v.0.12869) were retrieved from PanelApp Australia²⁷.

- 1022 Principal Component Analysis and Donut plots
- PCA plots were generated in Perseus v 1.6.14.0 from t-test fold-change data for VC
- 1024 cohort (Fig. 1B) or protein abundances for PBMCs controls (Fig. 4B). Donut plots were
- 1025 generated in GraphPad Prism (v.10.2.0).
- 1027 RNA sequencing and transcriptomic analysis
- 1028 RNA sequencing and analysis was performed as described²⁰. In brief, RNA was extracted
- 1029 from muscle using miRNeasy Mini Kit (Qiagen) and treated with RNase-Free DNase
- 1030 (Qiagen) and RNA quality and quantity measured using TapeStation RNA ScreenTape
- 1031 analysis (Agilent) and Qubit RNA HS (Thermo Fisher Scientific). UDP4 underwent
- 1032 RNAseg within a group of 10 undiagnosed patients with available muscle samples, all
- with an RNA integrity number of 7.2 8.9. The Kapa Biosystems mRNA Hyper Prep Kit
- was used to generate sequencing libraries from 500ng RNA, and paired-end sequencing

on an Illumina instrument was performed at the Yale Center of Genome Analysis to achieve 50-100 million read coverage.

For outlier detection, 100 control muscle samples were retrieved from GTEx using the Sequence Read Archive (SRA) toolkit and converted into FASTQ using Fastq-dump. Patient and control FASTQ files were aligned to hg38 human reference genome with GENCODE v26 annotations using STAR (v2.5.3a), with twopassMode = 'Basic' to enable detection of novel splice junctions, and duplicates marked using Picard (v2.9). RNA-SeQC (v2.3.4) was used to generate quality metrics from STAR-aligned bam files. Outliers were removed per the following criteria: (a) <45 million QC-passed reads, (b) <18,000 genes detected and (c) manual identification via Principal Component Analysis. This resulted in the removal of 11 samples, leaving 89 control samples from muscle. Outlier expression was assessed using the DROP (Detection of RNA Outliers Pipeline) pipeline v0.9.0 (https://github.com/gagneurlab/drop), with default settings⁸². Analysis was restricted to 6106 genes, which included Mendeliome and 'MitoExome' genes, as described previously²⁰.

cDNA studies

The total RNA extracted from skeletal muscle for RNA sequencing was also synthesized into cDNA using the SuperScript III First-Strand Synthesis System (Thermo Fisher Scientific) as per both manufacturer's protocols and as described previously⁸³. To examine mRNA splicing in *CCDC47*, PCR primers (5' GCGTGACTGAGCTACGGTT 3'; 5' CTCTGGGATGGCTTTACATGG 3') were designed to amplify the entire ORF from cDNA. PCR products were analyzed on 1% agarose (Bioline) gels using a 1-kb Plus DNA Ladder (Thermo Fisher Scientific) prior to cloning into a pCR2.1-TOPO vector using the TOPO TA cloning kit (Thermo Fisher Scientific) and transformation into TOP10 competent cells (Thermo Fisher Scientific). Individual colonies were examined and then underwent sanger sequencing.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

MitoMDT Diagnostic Network for Genomics and Omics

David R Thorburn, Aleksandra Filipovska, Michael T Ryan, David A Stroud, Diana Stojanovski, David Coman, Sean Murray, Ryan L Davis, John Christodoulou, Roula

- 1071 Ghaoui, Suzanne CEH Sallevelt, Cas Simons, Stefan J Siira, Shanti Balasubramaniam,
- 1072 Alison G Compton, Daniel G MacArthur, Nicole J Lake, Amanda Samarasinghe, Yoni
- 1073 Elbaum, Catherine Atthow, Pauline McGrath, Ellenore M Martin, Madeleine Harris, Tegan
- 1074 Stait, Leah E Frajman, Simone Tregoning
- 1076 **Author contribution**
- 1077 Conceptualization: DHH, DRT, DAS
- 1078 Methodology: DHH, NJC, LNS, NJL, LuEF, SSCA, TS, ST, LeEF, DRLR, MB, BoR, AGC,
- 1079 VK, CA

- 1080 Investigation: DHH, MB, BrR, MJW, AV, CB, HP, JL, ZS, RM, RWT, AGC, WB, NBT, MLF
- 1081 Visualization: DHH, NJC, LNS, NJL, SSCA
- 1082 Website design and coding: NJC
- 1083 Funding acquisition: DHH, JC, AGC, DRT, DAS
- 1084 Project administration: AS, RB, DRT, DAS
- Supervision: PM, ML, RM, RWT, MTR, ZS, JC, AGC, DRT, DAS
- 1086 Writing original draft: DHH, DRT, DAS
- 1087 Writing review & editing: all authors reviewed and edited the manuscript
- 1089 Funding

- 1090 This research was supported by Australian National Health and Medical Research
- 1091 Council (NHMRC) Project and Ideas grants (1140906 to DAS; 1164479 to DRT; 2010939
- 1092 to MTR), Investigator Fellowships (2009732 to DAS, 2010149 to LuEF and 1155244 to
- DRT) and a Principal Research Fellowship (1155244 to DRT) along with funding by
- 1094 Australian Genomics Health Alliance (Australian Genomics) NHMRC Targeted Call for
- 1095 Research grant GNT1113531. Additional support came from the Australian Medical
- 1096 Research Future Fund Genomics Health Futures Mission (2007959 to DRT) and Acute
- 1097 Care Genomics (GHFM76747). The US Department of Defense Congressionally Directed
- Medical Research Programs (PR170396 to DRT). We thank the Mito Foundation for the
- 1099 provision of instrumentation through research equipment grants to DAS and DHH.
- 1100 Additionally, LuEF acknowledges support from the Mito Foundation. This work was also
- Additionally, Euch acknowledges support from the Millo Foundation. This work was also
- supported by grants from Royal Children's Hospital Foundation [2021-1377]. Work at the MCRI is supported through the Victorian Government's Operational Infrastructure
- Troz mera le capportea anough ale victorian deverminente operational inflactional
- Support Program. RWT is funded by the Wellcome Centre for Mitochondrial Research
- 1104 (203105/Z/16/Z), the Mitochondrial Disease Patient Cohort (UK) (G0800674), the Medical
- 1105 Research Council (MR/W019027/1), the Lily Foundation, Mito Foundation, the
- 1106 Pathological Society, the UK NIHR Biomedical Research Centre for Ageing and Age-
- related disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust,

LifeArc and the UK NHS Highly Specialised Service for Rare Mitochondrial Disorders of Adults and Children.

Acknowledgments

1110 1111

1112

1113

1114

11151116

11171118

1119

112011211122

11271128

We acknowledge and thank all the families who contributed to this study. We thank all members of the Stroud and Stojanovski lab for input into experimental design and interpretation of data. We thank the Bio21 Mass Spectrometry and Proteomics Facility (MMSPF) for the provision of instrumentation, training, and technical support. The Chair in Genomic Medicine awarded to JC is generously supported by The Royal Children's Hospital Foundation. The authors thank staff of the Pathology Collection Department at The Royal Children's Hospital for obtaining the consent of participants and the collection of samples. The authors thank staff of the Anaesthetic and Surgical Departments at the Royal Children's Hospital.

Data Availability Statement

- 1123 The mass spectrometry proteomics data have been deposited to the ProteomeXchange
- 1124 Consortium via the PRIDE⁸⁴ partner repository with the dataset identifier PXD055473.
- De-identified genomic data from this study are available for ethically approved research.
- For queries about the genomic data sets please contact: david.thorburn@mcri.edu.au.

References

- 1129 1. Haack, T.B. *et al.* Molecular diagnosis in mitochondrial complex I deficiency using exome sequencing. *J Med Genet* **49**, 277-283 (2012).
- Taylor, R.W. *et al.* Use of whole-exome sequencing to determine the genetic basis of multiple mitochondrial respiratory chain complex deficiencies. *JAMA* **312**, 68-77 (2014).
- Ohtake, A. *et al.* Diagnosis and molecular basis of mitochondrial respiratory chain disorders: exome sequencing for disease gene identification. *Biochim Biophys Acta* **1840**, 1355-1359 (2014).
- Wortmann, S.B., Koolen, D.A., Smeitink, J.A., van den Heuvel, L. & Rodenburg, R.J.
 Whole exome sequencing of suspected mitochondrial patients in clinical practice. *J Inherit Metab Dis* 38, 437-443 (2015).
- Davis, R.L. et al. Use of Whole-Genome Sequencing for Mitochondrial Disease
 Diagnosis. Neurology 99, e730-e742 (2022).
- 1142 6. Frazier, A.E., Thorburn, D.R. & Compton, A.G. Mitochondrial energy generation 1143 disorders: genes, mechanisms, and clues to pathology. *J Biol Chem* **294**, 5386-5395 1144 (2019).
- 1145 7. Gorman, G.S. et al. Mitochondrial diseases. Nat Rev Dis Primers 2, 16080 (2016).
- 1146 8. Skladal, D., Halliday, J. & Thorburn, D.R. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. *Brain* **126**, 1905-1912 (2003).
- 1148 9. Smeets, H.J.M., Sallevelt, S. & Herbert, M. Reproductive options in mitochondrial disease. *Handb Clin Neurol* **194**, 207-228 (2023).

- 1150 10. Frazier, A.E., Vincent, A.E., Turnbull, D.M., Thorburn, D.R. & Taylor, R.W.
- Assessment of mitochondrial respiratory chain enzymes in cells and tissues.
- 1152 *Methods Cell Biol* **155**, 121-156 (2020).
- 1153 11. Kremer, L.S. et al. Genetic diagnosis of Mendelian disorders via RNA sequencing.
 1154 Nat Commun 8, 15824 (2017).
- 1155 12. Yepez, V.A. *et al.* Clinical implementation of RNA sequencing for Mendelian disease diagnostics. *Genome Med* **14**, 38 (2022).
- 1157 13. Fresard, L. *et al.* Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. *Nat Med* **25**, 911-919 (2019).
- 14. Murdock, D.R. et al. Transcriptome-directed analysis for Mendelian disease
 diagnosis overcomes limitations of conventional genomic testing. J Clin Invest 131
 (2021).
- 1162 15. Chen, E. et al. Rates and Classification of Variants of Uncertain Significance in Hereditary Disease Genetic Testing. *JAMA Netw Open* **6**, e2339571 (2023).
- 1164 16. Alston, C.L., Stenton, S.L., Hudson, G., Prokisch, H. & Taylor, R.W. The genetics of mitochondrial disease: dissecting mitochondrial pathology using multi-omic pipelines. *J Pathol* **254**, 430-442 (2021).
- 17. Kopajtich, R. et al. Integration of proteomics with genomics and transcriptomics increases the diagnostic rate of Mendelian disorders. medRxiv,
 2021.2003.2009.21253187 (2021).
- 1170 18. Xiao, Q. & Lauschke, V.M. The prevalence, genetic complexity and population-1171 specific founder effects of human autosomal recessive disorders. *NPJ Genom Med* 1172 **6**, 41 (2021).
- 1173 19. Sahni, N. *et al.* Widespread macromolecular interaction perturbations in human genetic disorders. *Cell* **161**, 647-660 (2015).
- 1175 20. Amarasekera, S.S.C. *et al.* Multi-omics identifies large mitoribosomal subunit 1176 instability caused by pathogenic MRPL39 variants as a cause of pediatric onset 1177 mitochondrial disease. *Hum Mol Genet* **32**, 2441-2454 (2023).
- 1178 21. Bakhshalizadeh, S. et al. Deficiency of the mitochondrial ribosomal subunit,
 1179 MRPL50, causes autosomal recessive syndromic premature ovarian insufficiency.
 1180 Hum Genet 142, 879-907 (2023).
- Helman, G. *et al.* Multiomic analysis elucidates Complex I deficiency caused by a deep intronic variant in NDUFB10. *Hum Mutat* **42**, 19-24 (2021).
- Horvath, R. *et al.* Childhood onset mitochondrial myopathy and lactic acidosis caused by a stop mutation in the mitochondrial cytochrome c oxidase III gene. *J Med Genet* **39**, 812-816 (2002).
- 1186 24. Van Haute, L. *et al.* TEFM variants impair mitochondrial transcription causing childhood-onset neurological disease. *Nat Commun* **14**, 1009 (2023).
- Lake, N.J. et al. Biallelic Mutations in MRPS34 Lead to Instability of the Small
 Mitoribosomal Subunit and Leigh Syndrome. Am J Hum Genet 101, 239-254 (2017).
- 1190 26. Stroud, D.A. *et al.* Accessory subunits are integral for assembly and function of human mitochondrial complex I. *Nature* **538**, 123-126 (2016).
- 1192 27. Martin, A.R. *et al.* PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. *Nat Genet* **51**, 1560-1565 (2019).

- 1194 28. Rath, S. *et al.* MitoCarta3.0: an updated mitochondrial proteome now with sub-1195 organelle localization and pathway annotations. *Nucleic Acids Res* **49**, D1541-1196 D1547 (2021).
- 1197 29. Granata, C. *et al.* High-intensity training induces non-stoichiometric changes in the 1198 mitochondrial proteome of human skeletal muscle without reorganisation of 1199 respiratory chain content. *Nat Commun* **12**, 7056 (2021).
- 1200 30. Thompson, K., Stroud, D.A., Thorburn, D.R. & Taylor, R.W. Investigation of oxidative 1201 phosphorylation activity and complex composition in mitochondrial disease. *Handb* 1202 *Clin Neurol* **194**, 127-139 (2023).
- 1203 31. Bernier, F.P. *et al.* Diagnostic criteria for respiratory chain disorders in adults and children. *Neurology* **59**, 1406-1411 (2002).
- 1205 32. Acin-Perez, R. *et al.* Respiratory complex III is required to maintain complex I in mammalian mitochondria. *Mol Cell* **13**, 805-815 (2004).
- 1207 33. Rahman, S. *et al.* Leigh syndrome: clinical features and biochemical and DNA abnormalities. *Ann Neurol* **39**, 343-351 (1996).
- 1209 34. Tucker, E.J. *et al.* Mutations in MTFMT underlie a human disorder of formylation causing impaired mitochondrial translation. *Cell Metab* **14**, 428-434 (2011).
- 1211 35. Massa, V. et al. Severe infantile encephalomyopathy caused by a mutation in
 1212 COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. Am J Hum Genet 82,
 1213 1281-1289 (2008).
- Hock, D.H., Robinson, D.R.L. & Stroud, D.A. Blackout in the powerhouse: clinical phenotypes associated with defects in the assembly of OXPHOS complexes and the mitoribosome. *Biochem J* **477**, 4085-4132 (2020).
- 1217 37. Zong, S. *et al.* Structure of the intact 14-subunit human cytochrome c oxidase. *Cell* 1218 *Res* (2018).
- 1219 38. Signes, A. & Fernandez-Vizarra, E. Assembly of mammalian oxidative
 1220 phosphorylation complexes I-V and supercomplexes. *Essays Biochem* 62, 255-270
 1221 (2018).
- 1222 39. Cizkova, A. *et al.* TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalocardiomyopathy. *Nat Genet* **40**, 1288-1290 1224 (2008).
- 1225 40. Catteruccia, M. *et al.* Persistent pulmonary arterial hypertension in the newborn 1226 (PPHN): a frequent manifestation of TMEM70 defective patients. *Mol Genet Metab* 1227 **111**, 353-359 (2014).
- 1228 41. Torraco, A. *et al.* TMEM70: a mutational hot spot in nuclear ATP synthase deficiency with a pivotal role in complex V biogenesis. *Neurogenetics* **13**, 375-386 (2012).
- 42. Braczynski, A.K. *et al.* ATP synthase deficiency due to TMEM70 mutation leads to
 ultrastructural mitochondrial degeneration and is amenable to treatment. *Biomed Res Int* **2015**, 462592 (2015).
- 1233 43. Magner, M. et al. TMEM70 deficiency: long-term outcome of 48 patients. J Inherit Metab Dis 38, 417-426 (2015).
- 1235 44. Sanchez-Caballero, L. *et al.* TMEM70 functions in the assembly of complexes I and V. *Biochim Biophys Acta Bioenerg* **1861**, 148202 (2020).

- 1237 45. Guerrero-Castillo, S. *et al.* The Assembly Pathway of Mitochondrial Respiratory Chain Complex I. *Cell Metab* **25**, 128-139 (2017).
- 1239 46. Mowat, D. *et al.* Respiratory chain complex III [correction of complex] in deficiency with pruritus: a novel vitamin responsive clinical feature. *J Pediatr* **134**, 352-354 (1999).
- 47. Morimoto, M. et al. Bi-allelic CCDC47 Variants Cause a Disorder Characterized by
 Woolly Hair, Liver Dysfunction, Dysmorphic Features, and Global Developmental
 Delay. Am J Hum Genet 103, 794-807 (2018).
- 1245 48. Yang, Q. *et al.* Clinical and genetic analysis of trichohepatoneurodevelopmental syndrome caused by a CCDC47 variant. *Heliyon* **10**, e27955 (2024).
- 1247 49. Iannello, G. et al. Simple, Fast, and Efficient Method for Derivation of Dermal
 1248 Fibroblasts From Skin Biopsies. Curr Protoc 3, e714 (2023).
- 1249 50. Amunts, A., Brown, A., Toots, J., Scheres, S.H.W. & Ramakrishnan, V. Ribosome.
 1250 The structure of the human mitochondrial ribosome. *Science* 348, 95-98 (2015).
- 1251 51. Bakker, H.D. *et al.* Human alpha-N-acetylgalactosaminidase (alpha-NAGA) 1252 deficiency: no association with neuroaxonal dystrophy? *Eur J Hum Genet* **9**, 91-96 1253 (2001).
- 1254 52. Sung, A.Y. *et al.* Systematic analysis of NDUFAF6 in complex I assembly and mitochondrial disease. *Nat Metab* **6**, 1128-1142 (2024).
- 1256 53. Pagliarini, D.J. *et al.* A mitochondrial protein compendium elucidates complex I disease biology. *Cell* **134**, 112-123 (2008).
- 1258 54. McKenzie, M. et al. Mutations in the gene encoding C8orf38 block complex I
 1259 assembly by inhibiting production of the mitochondria-encoded subunit ND1. J Mol
 1260 Biol 414, 413-426 (2011).
- 1261 55. Baide-Mairena, H. *et al.* Mutations in the mitochondrial complex I assembly factor NDUFAF6 cause isolated bilateral striatal necrosis and progressive dystonia in childhood. *Mol Genet Metab* **126**, 250-258 (2019).
- Hartmannova, H. et al. Acadian variant of Fanconi syndrome is caused by
 mitochondrial respiratory chain complex I deficiency due to a non-coding mutation
 in complex I assembly factor NDUFAF6. Hum Mol Genet 25, 4062-4079 (2016).
- 1267 57. Kim, J., Lee, J. & Jang, D.H. NDUFAF6-Related Leigh Syndrome Caused by Rare
 1268 Pathogenic Variants: A Case Report and the Focused Review of Literature. *Front*1269 *Pediatr* **10**, 812408 (2022).
- 1270 58. Nguengang Wakap, S. et al. Estimating cumulative point prevalence of rare
 1271 diseases: analysis of the Orphanet database. Eur J Hum Genet 28, 165-173 (2020).
- 1272 59. Van Bergen, N.J. et al. Severe NAD(P)HX Dehydratase (NAXD) Neurometabolic
 1273 Syndrome May Present in Adulthood after Mild Head Trauma. Int J Mol Sci 24 (2023).
- 1274 60. Tucker, E.J. et al. Premature Ovarian Insufficiency in CLPB Deficiency:
- Transcriptomic, Proteomic and Phenotypic Insights. *J Clin Endocrinol Metab* **107**, 3328-3340 (2022).
- 1277 61. Van Bergen, N.J. *et al.* Biallelic Variants in PYROXD2 Cause a Severe Infantile 1278 Metabolic Disorder Affecting Mitochondrial Function. *Int J Mol Sci* **23** (2022).
- 1279 62. Frazier, A.E. *et al.* Fatal perinatal mitochondrial cardiac failure caused by recurrent de novo duplications in the ATAD3 locus. *Med (N Y)* **2**, 49-73 (2021).

- 1281 63. Borna, N.N. *et al.* Mitochondrial ribosomal protein PTCD3 mutations cause oxidative phosphorylation defects with Leigh syndrome. *Neurogenetics* **20**, 9-25 (2019).
- 1284 64. Van Bergen, N.J. *et al.* Mutations in the exocyst component EXOC2 cause severe defects in human brain development. *J Exp Med* **217** (2020).
- 1286 65. Lunke, S. *et al.* Integrated multi-omics for rapid rare disease diagnosis on a national scale. *Nat Med* **29**, 1681-1691 (2023).
- 1288 66. Formosa, L.E., Dibley, M.G., Stroud, D.A. & Ryan, M.T. Building a complex complex:
 1289 Assembly of mitochondrial respiratory chain complex I. *Semin Cell Dev Biol* **76**,
 1290 154-162 (2018).
- Frederiksen, S.D. *et al.* Rare disorders have many faces: in silico characterization of rare disorder spectrum. *Orphanet J Rare Dis* **17**, 76 (2022).
- 1293 68. Turner, T.N. *et al.* Proteins linked to autosomal dominant and autosomal recessive 1294 disorders harbor characteristic rare missense mutation distribution patterns. *Hum* 1295 *Mol Genet* **24**, 5995-6002 (2015).
- 1296 69. Dofash, L.N. *et al.* Biallelic variants in HMGCS1 are a novel cause of rare rigid spine syndrome. *medRxiv*, 2023.2010.2025.23297129 (2023).
- 1298 70. Gorzynski, J.E. *et al.* Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting. *N Engl J Med* **386**, 700-702 (2022).
- 1300 71. Australian Genomics Health Alliance Acute Care, F. *et al.* Feasibility of Ultra-Rapid 1301 Exome Sequencing in Critically Ill Infants and Children With Suspected Monogenic 1302 Conditions in the Australian Public Health Care System. *JAMA* **323**, 2503-2511 1303 (2020).
- 1304 72. Dimmock, D. *et al.* Project Baby Bear: Rapid precision care incorporating rWGS in 5
 1305 California children's hospitals demonstrates improved clinical outcomes and
 1306 reduced costs of care. *Am J Hum Genet* **108**, 1231-1238 (2021).
- 1307 73. Guzman, U.H. *et al.* Ultra-fast label-free quantification and comprehensive proteome coverage with narrow-window data-independent acquisition. *Nat Biotechnol* (2024).
- 1310 74. Yang, Y. *et al.* Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *N Engl J Med* **369**, 1502-1511 (2013).
- 1312 75. Akesson, L.S. *et al.* Early diagnosis of Pearson syndrome in neonatal intensive care following rapid mitochondrial genome sequencing in tandem with exome sequencing. *Eur J Hum Genet* **27**, 1821-1826 (2019).
- 1315 76. Hoq, M. et al. A prospective, cross-sectional study to establish age-specific
 1316 reference intervals for neonates and children in the setting of clinical biochemistry,
 1317 immunology and haematology: the HAPPI Kids study protocol. BMJ Open 9,
 1318 e025897 (2019).
- 1319 77. Robinson, D.R.L. *et al.* Applying Sodium Carbonate Extraction Mass Spectrometry
 1320 to Investigate Defects in the Mitochondrial Respiratory Chain. *Front Cell Dev Biol* 1321 **10**, 786268 (2022).
- 1322 78. Kulak, N.A., Pichler, G., Paron, I., Nagaraj, N. & Mann, M. Minimal, encapsulated 1323 proteomic-sample processing applied to copy-number estimation in eukaryotic 1324 cells. *Nat Methods* **11**, 319-324 (2014).

1325	79.	Bruderer, R. et al. Extending the limits of quantitative proteome profiling with data-
1326		independent acquisition and application to acetaminophen-treated three-
1327		dimensional liver microtissues. <i>Mol Cell Proteomics</i> 14 , 1400-1410 (2015).

- Tyanova, S. & Cox, J. Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research. *Methods Mol Biol* **1711**, 133-148 (2018).
- 1330 81. Hulsen, T. arXiv:2210.04597 (2022).

- 1331 82. Yepez, V.A. *et al.* Detection of aberrant gene expression events in RNA sequencing data. *Nat Protoc* **16**, 1276-1296 (2021).
- 1333 83. Calvo, S.E. *et al.* Molecular diagnosis of infantile mitochondrial disease with targeted next-generation sequencing. *Sci Transl Med* **4**, 118ra110 (2012).
- 1335 84. Perez-Riverol, Y. *et al.* The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids Res* **50**, D543-D552 (2022).